Weekly Digest – October 2024 Weekly Digest – October 2024 24 Oct 2024: ABL Bio introduces platform tech to speed up developing bispecific ADCs ABL Bio has signed a technology transfer agreement with IntoCell, which specializes in ADC technology, to […]
Weekly Digest – October 2024 Weekly Digest – October 2024 24 Oct 2024: As DLL3 heats up, early data for Zai Lab’s ADC sets up case for differentiation Zai Lab is positioning its DLL3-targeting ADC ZL-1310 in the extensive-stage small-cell […]
Weekly Digest – October 2024 Weekly Digest – October 2024 23 Oct 2024: Hengrui initiated the phase II clinical study of nectin-4 ADC monotherapy for advanced gynecological tumors Hengrui has initiated a Phase II clinical study of SHR-A2102, an ADC […]
Weekly Digest – October 2024 Weekly Digest – October 2024 21 Oct 2024: Adcentrx Therapeutics announces FDA clearance of Investigational New Drug Application for ADRX-0405, a potential first-in-class ADC targeting STEAP1 for the treatment of advanced solid tumors Adcentrx Therapeutics […]
Weekly Digest – October 2024 Weekly Digest – October 2024 18 Oct 2024: Gilead pulls Trodelvy’s approval in bladder cancer after trial flop, FDA discussions Gilead Sciences has announced the withdrawal of Trodelvy as a treatment for bladder cancer in […]
